Additionally to its role in tumor bud formation and in the metastatic cascade, TGF-β1 participates in the development of treatment resistance following therapeutic EGFR inhibition via an impairment of immune responses in cooperation with prostaglandin E2 [68]. Here, EGFR is linked to neoplasm.